MC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategy On track to file IND in mid-2025 for a Phase 2b clinical trial in Hidradenitis...
Hyphens Pharma licenses Wynzora Cream for ASEAN countries from MC2 Therapeutics
MC2 Therapeutics to Present at Upcoming Conferences Copenhagen, February 26th, 2024 MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within...
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the...
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS is a first-in-class drug candidate for urea associated skin...
MC2-32 (RGRN-305) a first in class, oral therapy targeting multiple pathways involved in Hidradenitis Suppurativa (HS) achieves highly positive data in randomized, double-blinded, placebo-controlled...
MC2 Therapeutics’ drug candidate for hidradenitis suppurativa has shown hints of efficacy potential in a Phase IIa trial, sparking plans for Phase IIb development with a primary endpoint that may be a higher bar than previous approvals.
DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced that data from a 17-question survey sponsored by the Company was published in a poster entitled, “Improving Patient Acceptability and Adherence in Psoriasis Treatment,” at the 42nd Annual Fall Clinical Dermatology Conference® taking place October 20-23, 2022, in Las Vegas, NV.
MC2 Therapeutics has dosed the first subjects in a Phase II clinical trial of its drug candidate, MC2-25 Cream, for the treatment of moderate to severe chronic kidney disease-associated pruritus (CKD-aP) in stage 3-5 CKD patients.
DURHAM, N.C. and COPENHAGEN, Denmark, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, a Novan Company, and MC2 Therapeutics presented data from a previously unpublished subgroup analysis of the U.S. Phase 3 pivotal study of WYNZORA® Cream at the Skin of Color Update 2022 Conference held September 9-11, 2022, in New York, NY.